Table 1 Basic demographic characteristic of the study
Parameters | Cases (n/%) |
|---|---|
Age (y) | |
  < 60 | 81 (69.23) |
  ≥ 60 | 36 (30.67) |
Sex | |
 Male | 77 (65.81) |
 Female | 40 (34.19) |
Tumor location | |
 Right | 33 (28.21) |
 Left | 84 (71.79) |
Tumor morphology | |
 Ulcerated type | 57 (48.72) |
 Protruded type | 21 (17.95) |
 Mixed type | 6 (5.13) |
 Unknown | 33 (28.21) |
Histological differentiation | |
 Well + moderate | 92 (78.63) |
 Poor | 25 (21.37) |
Mucinous element | |
 With | 18 (15.39) |
 Without | 99 (84.61) |
Combined T stages | |
 T1 + T2 + T3 | 94 (80.34) |
 T4 | 23 (19.66) |
Combined N stages | |
 N0 | 30 (25.64) |
 N1+N2 | 87 (74.32) |
TNM stages | |
 II | 30 (25.64) |
 III | 87 (74.32) |
Tumor deposits | |
 With | 20 (17.09) |
 Without | 97 (82.91) |
RAS mutation | |
 Mutated | 6 (5.13) |
 Wild-type | 11 (9.40) |
 Unknown | 100 (85.47) |
MSS status | |
 MSI-H | 3 (2.56) |
 MSI-L + MSS | 66 (56.41) |
 Unknown | 48 (41.03) |
Ki-67 percentage | |
  ≥ 75% | 41 (35.04) |
 50–75% | 14 (11.97) |
 0–50% | 7 (5.98) |
 Unknown | 55 (47.01) |
Risk factors | |
 None | 58 (49.57) |
 1 | 34 (29.06) |
 2 | 15 (12.82) |
 3 | 9 (7.69) |
 4 | 1 (0.86) |
Adjuvant therapy regimens | |
 XELOX | 71 (60.83) |
 FOLFOX | 11 (9.40) |
 XELOX + X | 17 (14.53) |
 FOLFOX + X | 1 (0.85) |
 XELOX + FOLFOX | 8 (6.84) |
 X | 1 (0.85) |
 Others | 8 (6.70) |